| Literature DB >> 21448267 |
Anna Enblom1, Mats Lekander, Mats Hammar, Anna Johnsson, Erik Onelöv, Martin Ingvar, Gunnar Steineck, Sussanne Börjeson.
Abstract
BACKGROUND: It is not known whether or not delivering acupuncture triggers mechanisms cited as placebo and if acupuncture or sham reduces radiotherapy-induced emesis more than standard care. METHODOLOGY/PRINCIPALEntities:
Mesh:
Year: 2011 PMID: 21448267 PMCID: PMC3063156 DOI: 10.1371/journal.pone.0014766
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Selection of the patients in the standard care and the acupuncture cohort.
Clinical characteristics of the patients in the verum acupuncture, sham acupuncture or standard care group.
| Characteristics | Acupuncture cohort n = 215 | Standard care cohort n = 62 | Experiencing nausea n = 172/total n providing data = 2671 | Univariable relative risk (95 % confidence interval) | Multivariable2 relative risk, (95 % confidence interval) adjusted for three groups | |
| Verum acupuncture n = 109 | Sham acupuncture n = 106 | |||||
|
| n = 109 | n = 106 | n = 62 | n = 267 | ||
| Gynecological- | 72 (66) | 75 (71) | 37 (60) | 111/178 (62) | 1.0 (Ref.) | 1.0 (Ref.) |
| Colon-/rectal- | 31 (28) | 29 (27) | 11 (18) | 43/67 (64) | 1.0 (0.8–1.3) | 1.0 (0.8–1.3) |
| Testicular- | 2 (2) | 0 (0) | 6 (10) | 7/8 (88) | 1.4 (1.1–1.8) | 1.5 (1.0–2.2) |
| Pancreas, stomach or gallbladder-tumor | 4 (4) | 2 (2) | 8 (13) | 11/14 (79) | 1.3 (0.9–1.7) | 1.3 (0.9–1.9) |
|
| 47.9 ±10.7 | 50.3 ± 10.3 | 41.8 ± 10.0 | 47.3 ± 10.5 | ||
|
| n = 100 | n = 99 | n = 61 | n = 260 | ||
| Yes | 28 (28) | 29 (29) | 15 (25) | 57/72 (79) | 1.3 (1.1–1.6) | 1.3 (1.1–1.6) |
| No | 72 (72) | 70 (71) | 46 (75) | 112/188 (60) | 1.0 (Ref.) | 1.0 (Ref.) |
|
| n = 100 | n = 101 | n = 62 | n = 263 | ||
| No | 67 (67) | 69 (68) | 36 (58) | 74/162 (46) | 1.0 (Ref) | 1.0 (Ref) |
| Any type | 42 (42) | 37 (37) | 26 (42) | 98/105 (93) | 2.1 (1.7–2.4) | 2.0 (1.7–2.4) |
| Serotonin-receptor antagonists | 21 (21) | 23 (23) | 7 (11) | 48/51 (94) | 2.1 (1.7–2.5) | 1.6 (1.2–2.0) |
| Dopamine-receptor antagonists | 24 (24) | 21 (21) | 6 (10) | 48/51 (94) | 2.1 (1.7–2.5) | 2.1 (1.7–2.6) |
| Corticosteroids | 13 (13) | 25 (25) | 1 (2) | 34/39 (87) | 1.9 (1.6–2.3) | 1.9 (1.5–2.3) |
| Antihistamines or neuroleptics | 12 (12) | 9 (9) | 18 (29) | 37/39 (95) | 2.1 (1.7–2.5) | 1.6 (1.3–2.0) |
|
| n = 99 | n = 100 | n = 62 | n = 261 | ||
| Yes | 80 (80) | 88 (88) | 40 (65) | 140/208 (67) | 1.2 (0.9–1.5) | 1.2 (0.9–1.6) |
| No | 19 (19) | 12 (12) | 22 (35) | 30/53 (57) | 1.0 (Ref.) | 1.0 (Ref.) |
Numbers (n) of patients answering the questions are presented, 1267 of 277 patients provided data regarding nausea. Experiencing nausea was defined as any day within the radiotherapy period in the acupuncture cohort and within the past week in the standard care cohort. 2Including the variables seen in table 1 and 2. SD = Standard Deviation.
Personal characteristics of the patients in the verum acupuncture, sham acupuncture or standard care group.
| Characteristics | Acupuncture cohort n = 215 | Standard care cohort n = 62 | Experiencing nausea n = 172/total n providing data = 2671 | Univariable relative risk (95 % confidence interval) | Multivariable2 relative risk, (95 % confidence interval) adjusted for three groups | |
| Verum acupuncture n = 109 | Sham acupuncture n = 106 | |||||
|
| n = 109 | n = 106 | n = 62 | n = 267 | ||
| Man | 20 (18) | 15 (14) | 19 (31) | 35/53 (66) | 1.0 (0.8–1.3) | 1.0 (0.8 1.3) |
| Woman | 89 (82) | 91 (86) | 43 (69) | 137/214 (64) | 1.0 (Ref.) | 1.0 (Ref.) |
| Age in years: mean ± SD | 64 ± 13.8 | 63 ±13.9 | 63 ± 14.5 | 62 ± 14.8 | ||
| 19–40 | 7 (6) | 6 (6) | 6 (10) | 17/19 (89) | 1.5 (1.2–1.8) | 1.5 (1.2–2.0) |
| 41–60 | 34 (31) | 34 (32) | 17 (27) | 55/82 (67) | 1.1 (0.9–1.4) | 1.1 (0.9–1.3) |
| 61–89 | 68 (62) | 66 (62) | 39 (63) | 98/164 (60) | 1.0 (Ref.) | 1.0 (Ref.) |
|
| n = 106 | n = 104 | n = 62 | n = 257 | ||
| Employed | 35 (33) | 41 (38) | 21 (34) | 65/94 (69) | 1.2 (1.0–1.0) | 1.2 (1.0–1.4) |
| Retired/Sickness pension | 69 (65) | 59 (57) | 26 (42) | 82/142 (58) | 1.0 (Ref.) | 1.0 (Ref.) |
| Other | 2 (2) | 4 (4) | 15 (24) | 18/21 (86) | 1.5 (1.2–1.9) | 1.6 (1.1–2.1) |
|
| ||||||
|
| n = 96 | n = 97 | n = 62 | n = 256 | ||
| Not relevant | 55 (57) | 58 (60) | 43 (69) | 95/155 (61) | 1.0 (0.8–1.4) | 1.0 (0.8–1.4) |
| No | 11 (11) | 12 (12) | 15 (24) | 23/39 (59) | 1.0 (Ref.) | 1.0 (Ref.) |
| Yes | 30 (31) | 28 (29) | 4 (6) | 47/62 (76) | 1.3 (1.0–1.7) | 1.3 (0.9–1.7) |
|
| n = 89 | n = 92 | n = 61 | n = 242 | ||
| Not relevant | 26 (29) | 28 (30) | 33 (54) | 56/87 (64) | 1.3 (0.9–1.7) | 1.3 (1.1–1.9) |
| No | 19 (21) | 24 (26) | 6 (10) | 25/49 (51) | 1.0 (Ref.) | 1.0 (Ref.) |
| Yes | 44 (49) | 40 (43) | 22 (36) | 78/106 (74) | 1.4 (1.1–1.9 | 1.4 (1.1–1.9) |
|
| n = 96 | n = 98 | n = 61 | n = 256 | ||
| No | 22 (23) | 29 (30) | 17 (27) | 30/74 (41) | 1.0 (Ref.) | 1.0 (Ref.) |
| Yes | 74 (77) | 69 (70) | 44 (72) | 134/182 (74) | 1.8 (1.4–2–4) | 2.0 (1.3–3.3) |
|
| n = 972(1–3) | n = 982(1–3) | n = 612(0–3) | n = 2572(1–3) | ||
| 0–2 situations | 68 (70) | 67 (68) | 44 (71) | 110/179 (61) | 1.0 (Ref.) | 1.0 (Ref.) |
| 3–5 situations | 29 (30) | 31 (32) | 18 (29) | 56/78 (72) | 1.2 (1.0–1.4) | 1.2 (1.0–1.4) |
|
| n = 89 | n = 94 | not mea-sured | n = 183 | not relevant | |
| Lower than others | 19 (21) | 25 (27) | 22/44 (50) | 1.0 (Ref.) | ||
| Similar to others | 57 (64) | 55 (59) | 73/112 (65) | 1.3 (1.0–1.9) | ||
| Higher than others | 13 (15) | 14 (15) | 22/27 (81) | 1.6 (1.2–2.4) | ||
|
| n = 105 | n = 105 | not mea-sured | n = 201 | not relevant | |
| Do not believe | 0 (0) | 0 (0) | 0/0 (0) | |||
| Believe little | 5 (5) | 6 (6) | 4/10 (40) | 0.64 (0.3–1.4) | ||
| Believe moderately | 50 (46) | 57 (54) | 70/102 (68) | 1.1 (0.9–1.3) | ||
| Believe much | 50 (46) | 42 (40) | 56/89 (62) | 1.0 (Ref) | ||
|
| n = 109 | n = 101 | not mea-sured | n = 209 | not relevant | |
| Yes | 36 (33) | 36 (34) | 47/72 (65) | 1.1 (0.6–1.3) | ||
| No | 73 (66) | 65 (62) | 82/137 (60) | 1.0 (Ref) | ||
Numbers (n) of patients answering the questions are presented, 1267 of 277 patients provided data regarding nausea. Experiencing nausea was defined as any day within the radiotherapy period in the acupuncture cohort and within the past week in the standard care cohort. 2Including the variables seen in table 1 and 2. 3In travelling, unpleasant smells/sights, anxiety, chemotherapy or pregnancy. 4For other conditions than emesis. SD = Standard Deviation. Md = Median.
Figure 2Nausea and vomiting within the past 24 hours and the past week.
Emesis was measured at that time the radiotherapy dose was 27 Gray (mean) in the verum, sham and standard care groups. Measured in all patients and in patients not receiving potent antiemetics in the verum (n = 88 and n = 77), sham (n = 95 and n = 78) and standard care group (n = 62 and n = 55).
Comparison of nausea occurrence between the standard care cohort and the acupuncture cohort, adjusted for confounding factors for nausea.
| Nausea occurrence the past week | |
|
| 68 (37) |
|
| 39 (63) |
|
| 0.6 (0.5 |
|
| 0.3 (−0.7 |
|
| 0.4 (−0.1 |
|
| 0.3 (−0.2 |
|
| 0.8 (0.6 |
Relative risks for nausea (prevalence acupuncture cohort/ standard care cohort) during a cross sectional week of radiotherapy (mean dose 27 Gray in both cohorts). 1Verum and sham treated patients. 2Overall adjustment included adjustment for concomitant chemotherapy, age and nausea in any previous situation.
Figure 3Trust in the effect of the received treatment for preventing and reducing nausea.
The trust was stated at the sixth and the last verum or sham treatment in patients free from nausea and patients experiencing nausea after the sixth verum or sham treatment. Number of patients rating trust in antiemetic effects of received treatment at both the sixth and the last session was 183.